Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Gyawali, B., Sharma, S. & Booth, C. M. Is the number of cancer drug approvals a surrogate for regulatory success? J. Cancer Policy 22, 100202 (2019).
2. Gyawali, B., Hey, S. P. & Kesselheim, A. S. Evaluating the evidence behind the surrogate measures included in the FDA’s table of surrogate endpoints as supporting approval of cancer drugs. EClinicalMedicine 21, 100332 (2020).
3. Hwang, T. J. & Gyawali, B. Association between progression-free survival and patients’ quality of life in cancer clinical trials. Int. J. Cancer. 144, 1746–1751 (2019).
4. Burzykowski, T. & Buyse, M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm. Stat. 5, 173–186 (2006).
5. U.S. Food & Drug Administration. FDA approves neratinib for metastatic HER2-positive breast cancer. fda.gov https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer (2020).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献